Canada markets open in 3 hours 2 minutes

BioVaxys Technology Corp. (BIOV.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.3400-0.0100 (-2.86%)
At close: 3:40PM EDT
Full screen
Previous Close0.3500
Open0.0000
Bid0.3350 x N/A
Ask0.3700 x N/A
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume468,988
Market Cap26.133M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0640
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction
    CNW Group

    BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction

    BioVaxys Technology Corp. (CSE: BIOV) (CSE: BIOV.CN) (FRA: 5LB) (OTC: BVAXF) ("BioVaxys" or "Company") announced today that it has signed the definitive exclusive bioproduction agreement ("Agreement") with BioElpida S.A.S. ("BioElpida") of Lyon, France, to begin the clinical-grade bioproduction and aseptic packaging for BXV-0918A, BioVaxys' vaccine candidate for Stage III/Stage IV ovarian cancer. BioVaxys and BioElpida executed a Term Sheet in February outlining the commercial relationship, with todays definitive Agreement focusing on the GMP facility build-out in Lyon, and technical aspects of the bioproduction protocol such as process design and validation, quality control and quality assurance steps, batch test runs, stability testing, and aseptic fill. BioVaxys expects to be able to prepare its regulatory submission for a EU Phase I study of BVX-0918A in Stage III/Stage IV ovarian cancer near the end of this year, with vaccine supply for the planned clinical study available early May 2022.

  • Baystreet

    Stocks in play: BioVaxys Technology Corp.

    Announced today that it has filed with the United States Patent & Trademark Office ("USPTO") an intent-to-use ...

  • BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH Diagnostic
    CNW Group

    BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH Diagnostic

    BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: BVAXF) ("BioVaxys" or "the Company"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that it has filed with the United States Patent & Trademark Office ("USPTO") an intent-to-use application to register the mark CoviDTH®, it's novel disposable T-cell immune response diagnostic for SARS-CoV-2.